secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001193125-23-163060
Event type: litigation
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva concludes nationwide opioids settlement up to $4.25B; resolves all 50 states and >99% subdivisions
--------------------------------------------------------------------------------

- Teva will pay up to $4.25B over 13 years, including $1.2B of generic Narcan (or $240M cash) to participating states and subdivisions.
- Separate settlement with Nevada for $193M over 20 years, averting trial scheduled for August 2023.
- Settlement becomes effective August 7, 2023; first payments expected in H2 2023, with Narcan shipments already begun.
- Teva has now resolved opioid claims with all 50 U.S. states and more than 99% of litigating subdivisions and special districts.
- Agreement includes no admission of wrongdoing; company avoids further litigation uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312523163060/0001193125-23-163060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312523163060/d461805d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-163060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer